B

BioXcel Therapeutics

D

BTAI

USD

0.0297

(4.661%)

Market Closed

6,908.00

حجم التداول

-1.89

الربح لكل سهم

-

العائد الربحي

-0.192746

P/E

27,172,014.88

حجم السوق

اليوم

4.6610%

1 اسبوع

20.314%

1 شهر

-5.230%

6 اشهر

-75.436%

12 اشهر

-78.659%

بداية السنة

-77.470%

كل الوقت

-93.449%

أصول ذات صلة

Title:
BioXcel Therapeutics

Sector:

Healthcare

Industry:

Biotechnology

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

هل تحتاج مساعدة او لديك استفسار؟

تواصل معنا